Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ulcerative colitis (UC) and Crohn’s disease (CD).
Recent Posts
Categories
Related Articles
Eurozone November final CPI +2.2% vs +2.3% y/y prelim
Prior +2.0%Core CPI +2.7% vs +2.7% y/y prelimPrior +2.7%No changes to the...
ECB’s Lane: The argument for cutting by 50 bps was to show we are no longer restrictive
Forward rates curve shows that delivering on 2% target requires more rate...
Bitcoin Technical Analysis – Watch these risks for further upside
Fundamental OverviewBitcoin is now up more than 50% since the election day...
NZDUSD Technical Analysis – Awaiting the FOMC decision
Fundamental OverviewThe USD continues to consolidate around the highs except against the...
Leave a comment